News Headlines

  1. ADC Therapeutics Announces First Patients Dosed In Phase I/II Clinical Trial Of ADCT-602 In Relapsed Or Refractory B-Cell Acute Lymphoblastic Leukemia

    ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patients have been dosed in a Phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-602 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

  2. Cytokinetics Completes Enrollment In FORTITUDE-ALS, Phase 2 Clinical Trial Of Reldesemtiv In Patients With ALS

    Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial designed to assess the change from baseline in the percent predicted slow vital capacity (SVC) and other measures of skeletal muscle function after 12 weeks of treatment with reldesemtiv(formerly CK-2127107).

  3. Paratek Pharmaceuticals Doses First Patient In Phase 2 Clinical Trial Of Omadacycline In Acute Pyelonephritis, A Common Subset Of Complicated Urinary Tract Infections

    Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced dosing of the first patient in a Phase 2 study evaluating the potential efficacy and safety of oral and intravenous (IV) omadacycline for the treatment of acute pyelonephritis, a common subset of complicated urinary tract infections (cUTI).

  4. Aileron Enters Clinical Trial Collaboration With Pfizer To Evaluate ALRN-6924 In Combination With IBRANCE® (Palbociclib) In MDM2-Amplified Cancers

    Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases, today announced that it has entered into a clinical trial collaboration with Pfizer to evaluate the combination of Aileron’s ALRN-6924 and Pfizer’s palbociclib, also known as IBRANCE®, in MDM2-amplified cancers.

  5. FDA Approves An Oncology Drug That Targets A Key Genetic Driver Of Cancer, Rather Than A Specific Type Of Tumor

    The U.S. Food and Drug Administration recently granted accelerated approval to Vitrakvi(larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker).

  6. G1 Therapeutics Announces Positive Myelopreservation Data From Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Of Trilaciclib In Combination With Chemotherapy/Tecentriq® In First-Line Small Cell Lung Cancer

    G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced positive topline data from its randomized, double-blind, placebo-controlled Phase 2 trial evaluating trilaciclib in combination with chemotherapy and the checkpoint inhibitor Tecentriq® (atezolizumab) as a treatment for 1L SCLC.

  7. Creation Of Unified Health Record Now Achievable With Ciox HealthSource Vault

    Ciox, a leading health technology company, recently announces the general availability of Ciox HealthSource Vault, a unified member-centric data repository designed for health plans, self-funded employers, life sciences companies and government agencies that require ubiquitous access to clinical data.

  8. Lyndra Therapeutics Reports Positive Results From Pharmacokinetics (PK) Study Of Its Ultra-Long-Acting Oral Dosage Form

    Lyndra Therapeutics, which aims to make daily pills a thing of the past, has released positive results from a pharmacokinetics (PK) study of its ultra-long-acting oral dosage form.

  9. Opthea Completes Patient Recruitment Ahead Of Schedule In Phase 2b Wet AMD Clinical Trial

    Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, today announced that recruitment into the Company’s ongoing Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) is complete.

  10. TG Therapeutics Announces Phase I Study Of Novel BTK Inhibitor, TG-1701, In Patients With Relapsed Or Refractory B-Cell Malignancies Is Open For Enrollment

    TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the first Company sponsored Phase I study of its novel, orally available and covalently-bound Bruton Tyrosine Kinase (BTK) inhibitor, TG-1701, is open for enrollment for patients with relapsed or refractory B-cell malignancies.